id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312057-4zfaqkxm	Leppla, Idris E.	Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2)	2020-05-14		.txt	text/plain	1666	90	50	In the setting of COVID-19, opioid use disorder treatment paradigms are being disrupted, including the fact that methadone clinics are scrambling to give "take-home" doses where they would typically not. The rapid transition away from in-person examination, dosing and group therapy in an era of social isolation calls for adjustments to clinical practice, including emphasizing patient-provider communication, favoring new inductees on buprenorphine and leveraging technology to optimize safety of medication treatment. COVID-19 (SARS-CoV-2) is disrupting opioid use disorder (OUD) treatment paradigms, which have traditionally relied on in-person examination, medication dispensing, counseling sessions, and group therapy. We review and provide guidance for clinicians regarding 3 prongs of medication treatment of OUD affected by COVID-19 healthcare mandates: methadone take-homes, buprenorphine treatment, and antagonist therapy. FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency	./cache/cord-312057-4zfaqkxm.txt	./txt/cord-312057-4zfaqkxm.txt